<DOC>
	<DOC>NCT01077661</DOC>
	<brief_summary>An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information</brief_summary>
	<brief_title>Regulatory Nebilet PMS</brief_title>
	<detailed_description>An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information Nebivolol will be administered to Hypertension or Chronic heart failure (CHF) patients as described the prescribing information of Nebivolol by physician's decision.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>All subjects must satisfy the following criteria at PMS entry according to KFDA PMS regulation: Subjects with indication in the prescribing information Subjects administrated Nebivolol by physician's decision Subjects with no contraindication according to the prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>PMS (post-marketing surveillance)</keyword>
</DOC>